Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.3652W HIGH $3.15
Volume
71.10 K
Value Traded
18.93 K
Short % Float
0.89%
-10.79%Week
-34.56%1 Month
-54.96%3 Month
-77.31%6 Month
-88.22%5 Year
-88.22%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
18.16 M
EPS (TTM)
-0.23
P/E Ratio
-
Ent. Value
18.01 M
Total Shares
43.50 M
Float Shares
17.22 M
Insiders
60.42%
Institutions
11.02%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
ESLA Catalyst Timeline
Dated clinical, regulatory and corporate events for Estrella Immunopharma, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Estrella Immunopharma, Inc.
37Total events
4Upcoming
8Tier-1 (high impact)
2022 to 2026Coverage
Upcoming catalysts 2
TBD
T2DSMB Review
Subscribe to view catalyst details
TBD
T2Trial Initiation
Subscribe to view catalyst details
Event history 33
▲Trial InitiationEB103Trial
Activation of University Hospitals Cleveland Medical Center as fourth clinical site for STARLIGHT-1 trial
relapsed or refractory B-cell non-Hodgkin's lymphomasource ↗
▲Trial InitiationEB103Trial
Oregon Health & Science University activated as third clinical site for STARLIGHT-1
relapsed or refractory B-cell non-Hodgkin's lymphomasource ↗
▲Enrollment UpdateEB103Trial
OHSU site begins screening and enrolling patients in STARLIGHT-1
relapsed or refractory B-cell non-Hodgkin's lymphomasource ↗
▲Trial InitiationEB103Trial
Activation of Baylor Scott & White Research Institute as second clinical site for STARLIGHT-1 trial
relapsed or refractory B-cell non-Hodgkin's lymphomasource ↗
▲First Patient DosedEB103Trial
First patient dosed in dose-expansion phase of STARLIGHT-1 trial
relapsed/refractory B-cell non-Hodgkin's lymphomasource ↗
▲Full ResultsEB103Clinical Data
Encouraging efficacy data from dose-escalation cohort: all evaluable patients with no CNS involvement who achieved CR remained in CR at 6 months
relapsed/refractory B-cell non-Hodgkin's lymphomasource ↗
◆Oral PresentationPresentation
Estrella Immunopharma to participate in D. Boral Capital Global Conference
▲Oral PresentationEB103Presentation
Oral presentation of updated STARLIGHT-1 Phase I results at 2026 Tandem Meetings
aggressive B-cell Non-Hodgkin Lymphoma (NHL)source ↗
▲Oral PresentationEB103Presentation
Oral presentation of updated STARLIGHT-1 Phase I results at 2026 Tandem Meetings
aggressive B-cell Non-Hodgkin Lymphomasource ↗
◆Late-BreakerEB103Presentation
Late-breaking abstract available online
aggressive B-cell Non-Hodgkin Lymphomasource ↗
◆Oral PresentationEB103Presentation
Late-breaking oral presentation of Phase 1 STARLIGHT-1 data at 2026 Tandem Meetings
aggressive B-cell Non-Hodgkin Lymphomasource ↗
◆Oral PresentationEB103Presentation
Late-breaking oral presentation of Phase 1 STARLIGHT-1 data at 2026 Tandem Meetings
aggressive B-cell Non-Hodgkin Lymphomasource ↗
▼Equity OfferingCorporate
Announced $8.0 million registered direct offering and concurrent private placement
▲DSMB ReviewEB103Trial
DSMB completed review of Phase I safety data and recommended advancement to Phase II
relapsed/refractory B-cell non-Hodgkin's lymphomasource ↗
▲Trial InitiationEB103Trial
Phase II expansion phase of STARLIGHT-1 initiated
relapsed/refractory B-cell non-Hodgkin's lymphomasource ↗
▲Enrollment CompleteEB103Trial
Completed second dose cohort in Phase I portion of STARLIGHT-1 trial
Advanced B-Cell Non-Hodgkin's Lymphomassource ↗
▲Enrollment UpdateEB103Trial
Activation of second clinical site (Baylor Research Institute) for STARLIGHT-1 trial
relapsed or refractory B-cell non-Hodgkin's lymphomasource ↗
▲First Patient DosedEB103Trial
First patient dosed in second cohort of STARLIGHT-1 trial
Advanced B-Cell Non-Hodgkin's Lymphomassource ↗
▲Enrollment MilestoneEB103Trial
Initiation of second cohort in STARLIGHT-1 trial
Advanced B-Cell Non-Hodgkin's Lymphomassource ↗
▲Enrollment CompleteEB103Trial
Completed first dose cohort in STARLIGHT-1 trial
relapsed/refractory B-cell non-Hodgkin lymphomasource ↗
▲DSMB ReviewEB103Trial
DSMB approved initiation of second dose cohort
relapsed/refractory B-cell non-Hodgkin lymphomasource ↗
◆Trial InitiationEB103Trial
Initiation of second dose cohort (5 million receptor-positive T cells/kg)
relapsed/refractory B-cell non-Hodgkin lymphomasource ↗
▲First Patient DosedEB103Trial
First patient dosed in Phase I/II trial of EB103 for R/R B-cell NHL
relapsed/refractory B-cell Non-Hodgkin's Lymphomassource ↗
▲First Patient DosedEB103Trial
First patient dosed in Phase I/II STARLIGHT-1 trial of EB103
relapsed or refractory B-cell Non-Hodgkin's Lymphomasource ↗
◆AcquisitionCorporate
Stockholder meeting to approve business combination with Estrella Biopharma
◆AcquisitionCorporate
Deadline for public stockholders to deliver redemption requests for extension proposal
Past FDA Catalysts and PDUFA Decisions
How ESLA actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-02-04 | EB103 | Phase 1 data readout | Phase 1 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
F12 / 100
Pipeline Score
$0M
Pipeline Value
Richly Valued
Valuation Signal
1
Drugs Scored
0.0x
rNPV / MCap
Top 99%
Micro Cap(rank 651 of 658)
Percentile Rank
Estrella Immunopharma, Inc. has significant pipeline risk (12/100), with $61M risk-adjusted pipeline value, led by EB103 in B-Cell Non-Hodgkin's Lymphoma (NHL) (Phase 1), but cash runway is a concern.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EB103 Monoclonal antibodyNCT06343311 | B-Cell Non-Hodgkin's Lymphoma (NHL) | Phase 1 | RECRUITING | 27 | Jul 31, 2028 |
Clinical Trial Results
Readouts, endpoints and source filings for every ESLA program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| EB103 | B-cell Non-Hodgkin Lymphoma | Phase 1 | 2026-02-10 | Complete Response rate: 100%; n: 9; Duration of Complete Response: 3 to 18 monthsRead More | Estrella Immunopharma Presents Promising Updated Data on EB103 in Oral Presentation at the 2026 Tandem Meetings of ASTCT® & CIBMTR®Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Liu ChengDirector, Officer (CEO) | Option | 100,000 900,000 held | $0.00 | 08/25/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ESLA
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in ESLA for Q2 2026. | ||||
ESLA Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ESLA ranks across every disease it competes in
Competitive Position is a premium feature
See how ESLA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialESLA News
ESLAEstrella Immunopharma Activates University Hospitals Cleveland Medical Center as Fourth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
Estrella Immunopharma has activated a fourth clinical site at University Hospitals Cleveland Medical Center for its STARLIGHT-1 Phase I/II trial. This trial is assessing EB103, a CD19-Redirected ARTEMIS® T-cell therapy, aimed at treating patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. The expansion of clinical sites is expected to facilitate patient recruitment and enhance study outcomes.
Read more →ESLAEstrella Immunopharma Activates Oregon Health & Science University as Third Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
Estrella Immunopharma has activated Oregon Health & Science University as the third clinical site for its STARLIGHT-1 Phase I/II trial. This trial is focused on evaluating EB103, a CD19-Redirected ARTEMIS® T-cell therapy, in patients suffering from relapsed or refractory B-cell non-Hodgkin's lymphoma. The expansion of clinical sites is expected to enhance patient recruitment and trial outcomes.
Read more →ESLAEstrella Immunopharma Activates Baylor Scott & White Research Institute as Second Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
Estrella Immunopharma has activated Baylor Scott & White Research Institute as the second clinical site for its STARLIGHT-1 Phase I/II trial. This trial is focused on evaluating EB103, a CD19-Redirected ARTEMIS® T-cell therapy, for patients suffering from relapsed or refractory B-cell non-Hodgkin's lymphoma. The expansion of clinical sites aims to enhance patient recruitment and accelerate the trial process.
Read more →ESLAEstrella Immunopharma Announces First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial and Reports Durable Response Rate in Advanced B-Cell Non-Hodgkin’s Lymphoma
Estrella Immunopharma has announced the successful dosing of the first patient in the dose-expansion phase of its STARLIGHT-1 Phase I/II clinical trial. The trial evaluates EB103, a CD19-redirected ARTEMIS T-cell therapy, specifically for patients with relapsed or refractory advanced B-cell non-Hodgkin's lymphoma. The company also reported a durable response rate in this patient population.
Read more →ESLA▼ -8.1%on this news
Estrella Immunopharma to Participate in the D. Boral Capital Global Conference
Estrella Immunopharma is set to participate in the D. Boral Capital Global Conference. Details regarding the conference agenda or specific topics of discussion have not been provided. The participation indicates the company's ongoing engagement with investors and stakeholders in the biopharma sector.
Read more →ESLAEstrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Initiating Coverage with a Valuation of $12.00/Share from Zacks Small-Cap Research
Estrella Immunopharma, Inc. has received initiating coverage from Zacks Small-Cap Research, which has assigned a valuation of $12.00 per share. This coverage emphasizes the company's focus on developing CD19 and CD22-targeted ARTEMIS® T-cell therapies aimed at treating cancer and autoimmune diseases. The report reflects a positive outlook for the company's future.
Read more →ESLAEstrella Immunopharma Presents Promising Updated Data on EB103 in Oral Presentation at the 2026 Tandem Meetings of ASTCT® & CIBMTR®
Estrella Immunopharma presented encouraging results for EB103 at the 2026 Tandem Meetings, showcasing a 100% Complete Response rate in high-risk B-cell Non-Hodgkin Lymphoma patients. The STARLIGHT-1 Phase I study reported no serious adverse events, highlighting EB103's safety and potential as a transformative therapy. The findings suggest significant promise for broader patient populations.
Read more →ESLA▼ -11.1%on this news· ran to +22% by day 3shared move
Estrella Immunopharma Announces Late-Breaking Oral Presentation of Phase 1 STARLIGHT-1 Data for EB103 at the 2026 Tandem Meetings of ASTCT® & CIBMTR®
Estrella Immunopharma announced that its STARLIGHT-1 Phase 1 study results for EB103 will be presented at the 2026 ASTCT & CIBMTR Tandem Meetings. This study focuses on a novel T-cell therapy targeting CD19 in patients with aggressive B-cell Non-Hodgkin Lymphoma. The late-breaking abstract will be available on February 4, 2026.
Read more →ESLAEstrella Immunopharma Announces $8.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
Estrella Immunopharma, Inc. announced an $8 million registered direct offering and concurrent private placement, intended to fund its clinical-stage development of CD19 and CD22-targeted ARTEMIS T-cell therapies. The direct offering includes securities priced at-the-market under Nasdaq rules. The transactions are expected to close on January 6, 2026, and will assist in general corporate purposes and working capital. Aegis Capital Corp. is the exclusive placement agent for these offerings.
Read more →ESLAEstrella Immunopharma, Inc. Announces $8.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
Estrella Immunopharma, Inc. has announced a registered direct offering and concurrent private placement expected to generate approximately $8.0 million. The transactions involve the sale of common stock and pre-funded warrants to a single institutional investor. The proceeds will be utilized for general corporate purposes and working capital, with the closing anticipated on January 6, 2026.
Read more →ESLA▲ +12.2%on this news· ran to +23% by day 3
Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation
Estrella Immunopharma has received a positive recommendation from an independent Data Safety Monitoring Board to advance its STARLIGHT-1 trial into Phase II. This decision follows a successful Phase I dose escalation, where EB103 demonstrated a 100% complete response rate in high-risk patients. The Phase II expansion will further assess the safety and efficacy of the therapy in relapsed/refractory B-cell non-Hodgkin's lymphoma.
Read more →ESLA▲ +7.8%on this news
Estrella Immunopharma Completes Second Dose Cohort in STARLIGHT-1 Trial of EB103 with Complete Responses in All
Estrella Immunopharma has announced the successful completion of the second dose cohort in the STARLIGHT-1 Phase I/II clinical trial for EB103, a T-cell therapy targeting B-cell Non-Hodgkin's Lymphomas. The trial reported a 100% complete response rate among evaluable patients, highlighting the effectiveness of EB103. The safety profile observed during the trial is encouraging, particularly for high-risk patients, indicating potential for a wider application of the therapy. A Data and Safety Monitoring Board will review the findings to determine the next steps for the trial's expansion phase.
Read more →ESLA▲ +7.1%on this news
Estrella Immunopharma Announces Activation of Additional Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin's Lymphoma
Estrella Immunopharma has announced the activation of an additional site for its Phase I/II STARLIGHT-1 trial, which evaluates the EB103 therapy for relapsed or refractory B-cell non-Hodgkin's lymphoma. The new site, located at the Baylor Research Institute in Dallas, Texas, will now facilitate patient enrollment. This expansion is seen as a significant step in accelerating the trial's development and enhancing patient accessibility to the T-cell therapy. The study assesses the safety and optimal dosing of EB103, which targets CD19-positive cancer cells.
Read more →ESLA▼ -14%on this newsshared move
Estrella Immunopharma Announces Approximately
Estrella Immunopharma has announced a private placement equity financing expected to raise about $3.35 million. The proceeds will be utilized for advancing the STARLIGHT-1 clinical trial of their CD19-redirected ARTEMIS T-cell therapy, EB103, aimed at treating relapsed/refractory B-cell non-Hodgkin's lymphoma. The company plans to issue 2,333,334 shares at $1.50 each. The financing reflects investor confidence in Estrella's innovative immunotherapy approach.
Read more →ESLA▲ +5.2%on this newsshared move
Estrella Immunopharma Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103 in Advanced B-Cell Non-Hodgkin's Lymphomas Emeryville, California
Estrella Immunopharma has announced the dosing of the first patient in the second cohort of its STARLIGHT-1 trial for EB103, a CD19-redirected T-cell therapy aimed at treating Advanced B-Cell Non-Hodgkin's Lymphomas. This phase of the trial comes after favorable safety data from the initial cohort, which showed no dose-limiting toxicities or serious adverse events. The trial's progress is seen as a significant milestone in Estrella's goal to offer new treatment options for patients, particularly those typically excluded from traditional CAR-T therapies.
Read more →ESLAEstrella Immunopharma Completes First Dose Cohort in STARLIGHT-1 Trial and Receives Approval to Initiate Higher Dose Cohort
Estrella Immunopharma has successfully completed the first dose cohort in its STARLIGHT-1 Phase I/II clinical trial, focusing on EB103 T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma. The Data and Safety Monitoring Board approved the next higher dose cohort based on favorable safety and efficacy data, which shows no serious adverse events reported. Preliminary results indicate a tumor response in all treated patients at the one-month mark. This advancement highlights the potential of EB103 as a promising therapeutic option in oncology.
Read more →ESLAEstrella Immunopharma Announces Appointment of Hong Zhang as Chairperson and Board Member
Estrella Immunopharma has appointed Hong Zhang as Chairperson and Board Member, increasing its board from five to six directors. This strategic move follows the dosing of the first patient in the Phase I/II clinical trial for EB103, an innovative T-cell therapy targeting B-cell Non-Hodgkin's Lymphoma. Ms. Zhang brings over 25 years of financial and corporate strategy experience, aiming to strengthen Estrella's mission of developing advanced therapies. CEO Cheng Liu expressed confidence in Zhang's contributions towards the company’s growth and advancement of its therapeutic pipeline.
Read more →ESLAEstrella Immunopharma Doses First Patient in Phase I/II Trial of Anti-CD19 ARTEMIS T-cells in Advanced B-cell Non-Hodgkin's Lymphomas (STARLIGHT-1)
Estrella Immunopharma announced the dosing of the first patient in its Phase I/II clinical trial for EB103, an autologous T-cell therapy aimed at treating relapsed/refractory B-cell Non-Hodgkin's Lymphomas. The trial, named STARLIGHT-1, will evaluate the safety and effectiveness of the therapy, which employs ARTEMIS technology. Experts highlight its potential to provide a safer treatment option compared to traditional CAR-T therapies, particularly for high-risk patients. This milestone marks a significant step in developing advanced treatment options for patients with limited existing alternatives.
Read more →About Estrella Immunopharma, Inc.
Headquarters5858 HORTON STREET, SUITE 370, EMERYVILLE, CA, 94608
BIOPHARMAWATCH ELITE PLUS
Trade the next ESLA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime